Is anyone interested in coming to work with the amazing crowd at the Cuella Martin lab and our cool projects? An RA position will open soon, stay tuned!

In the latest issue! TERT activation targets DNA methylation and multiple aging hallmarks dlvr.it/TB8gqk

Online now: PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis dlvr.it/TCTsBb

Now online! Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy dlvr.it/TDF4WJ

The 2024 Albert Lasker Award for Basic Medical Research recognizes Dr. Zhijian (James) Chen for his elucidation of how DNA stimulates immune responses. Learn more about this award-winning research: nej.md/4e9pCEt

cell.com/immunity/fullt…

Excited to share: "Mapping multimodal phenotypes to perturbations in cells and tissue with CRISPRmap", just published in Nature Biotechnology. Spearheaded by Jiacheng Gu, and powered by everyone in the Gaublomme Laboratory at Columbia Biological Sciences and collaborators. tinyurl.com/4zx95v3a

Aging senescent cells do not become hypometabolic Instead they become HYPERmetabolic, burning energy faster than their younger selves This likely steals energy for other useful cellular functions, possibly accounting for their aberrant behaviors nature.com/articles/s4358…

ecDNA are rogue genetic material that amplify genes, contribute to treatment resistance and drive genomic heterogeneity. We report on the Origins and impact of extrachromosomal DNA today in nature nature.com/articles/s4158…

Check out the 2025 lineup of Social DNAing! Exciting new talks. We will also host 4 webinars in collaboration with NAR/NAR Cancer Bill Dynan - NAR Cancer Editor to celebrate their 5-year birthday! Full programs will be on the website in 10 days. Stay tune.

Advances in cancer immunotherapies Cell

Now out in Genome Medicine BMC. Transform your #crispr screens with "Exorcise", EXOme-guided Re-annotation of nuCleotIde SEquences, doi.org/10.1186/s13073….

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy. Read the full CheckMate 8HW trial results: nej.md/4eGp1tj

🚨So proud to present the first study from our Computational Cancer Genomics (CCG) Research Group group together with Charles Swanton Nnennaya Kanu and led by Olivia Lucas with key collaboration Sophie Ward and fundamental support Rija Zaidi Abi Bunkum & many others Out in Nature Genetics 👇 doi.org/10.1038/s41588… 🧵👇

Managing allorejection in Off-the-Shelf CAR-engineered cell therapies doi.org/10.1016/j.ymth… REVIEW Molecular Therapy

Could one envision a synthetic receptor technology that is fully programmable, able to detect diverse extracellular antigens – both soluble and cell-attached – and convert that recognition into a wide range of intracellular responses, from transgene expression and real-time

EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models dlvr.it/TJSx1B

I'm happy to share that I've joined IFOM as a Junior Group Leader, leading the Functional Genomics of Cancer Immunity Laboratory! 🔬 The lab investigates the links between DNA damage response (DDR) and cancer immunity. Exciting times are ahead—stay tuned!

God Bless America 🇺🇸